Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CALCIUM GLUCONATE IN SODIUM CHLORIDE vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Calcium gluconate provides calcium ions, which are essential for normal cardiac function, nerve transmission, and muscle contraction. In hyperkalemia, calcium antagonizes the cardiotoxic effects of potassium by stabilizing the cardiac cell membrane.
Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.
Emergency treatment of hypocalcemia,Treatment of hypermagnesemia,Treatment of calcium channel blocker overdose,Treatment of hyperkalemia (as a cardioprotective agent),Off-label: Treatment of hydrofluoric acid burns,Off-label: Treatment of black widow spider envenomation
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., emphysema, chronic bronchitis),Adjunctive therapy in acute bronchial asthma and status asthmaticus,Off-label: Treatment of apnea of prematurity
1-2 g calcium gluconate (9.3-18.6 m Eq calcium) intravenously over 10-20 minutes, may repeat if needed. For continuous infusion: 0.5-2 mg/kg/hour calcium gluconate. Max rate: 1-2 m L/minute of 10% solution.
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.
Terminal elimination half-life is 6-8 hours in patients with normal renal function; prolonged in renal impairment (up to 24-48 hours).
Terminal elimination half-life: 3-12 hours in adults (mean 5-6 hours); prolonged in hepatic impairment, heart failure, COPD, and neonates (up to 30 hours). Smoking reduces half-life by 30-50%.
Not metabolized; calcium is excreted primarily in urine and feces.
Theophylline is metabolized primarily in the liver by cytochrome P450 isoenzymes, predominantly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism involves N-demethylation and oxidation. In neonates, metabolism is immature; in adults, ~90% is hepatically cleared. Ethylenediamine is minimally metabolized.
Primarily renal; ~80% of administered calcium is excreted in urine via glomerular filtration with tubular reabsorption; fecal excretion accounts for ~15-20% as unabsorbed or secreted calcium; negligible biliary excretion.
Renal excretion of unchanged drug (about 10-20%) and metabolites (primarily 1,3-dimethyluric acid, 1-methyluric acid, 3-methylxanthine). Billary/fecal excretion is negligible.
Approximately 45-50% bound to albumin; also binds to globulins and other proteins.
Theophylline (active moiety): approximately 40% bound to plasma proteins, primarily albumin. Protein binding decreases in neonates, hepatic cirrhosis, and uremia.
0.15-0.25 L/kg; reflects distribution primarily in extracellular fluid; increases in conditions with increased capillary permeability.
Apparent volume of distribution: approximately 0.4-0.6 L/kg (average 0.45 L/kg). Indicates distribution into total body water; slightly higher in neonates and premature infants.
Intravenous: 100% (complete systemic availability); not administered orally for systemic effect due to poor bioavailability; calcium gluconate oral absorption is ~30% but not relevant for this formulation.
Oral: 96-100% for immediate-release tablets; 50-70% for some sustained-release formulations depending on formulation. Rectal: 70-80% (variable). IV: 100%.
No specific dose reduction required; monitor serum calcium and phosphate levels. In severe renal impairment (Cr Cl <30 m L/min), use with caution due to risk of calcium loading and soft tissue calcification.
No dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce maintenance dose by 50% and monitor serum theophylline levels. For GFR <10 m L/min: reduce maintenance dose by 50% and extend dosing interval or use with caution.
No dose adjustment required for hepatic impairment. Calcium gluconate is not hepatically metabolized.
Child-Pugh A: reduce dose by 50%. Child-Pugh B: reduce dose by 75%. Child-Pugh C: contraindicated or use with extreme caution, reduce dose by 80% and monitor levels.
Neonates and infants: 200-500 mg/kg/day intravenously as a continuous infusion or in divided doses. Children: 500-1000 mg/kg/day intravenously; maximum single dose 1 g. Administer slowly (not exceeding 0.5-1 m L/min of 10% solution).
Loading dose: 1 mg/kg IV (if not on theophylline). Maintenance: Continuous infusion: age 6 months-1 year: 0.5 mg/kg/h; age 1-9 years: 0.8 mg/kg/h; age 9-12 years: 0.7 mg/kg/h; age 12-16 years: 0.6 mg/kg/h. Maximum daily dose: 24 mg/kg/day.
No specific dose adjustment; administer at lower end of dosing range due to potential renal impairment. Monitor serum calcium, magnesium, and phosphate levels regularly. Infuse at a slower rate (e.g., over 20-30 minutes per gram).
Consider lower initial doses due to decreased clearance. Use ideal body weight. Start at lower maintenance infusion rate (e.g., 0.3 mg/kg/h) and titrate based on serum levels and clinical response. Monitor for toxicity.
No FDA boxed warning.
None
Risk of cardiac arrest or arrhythmia if administered too rapidly intravenously,Extravasation may cause tissue necrosis or sloughing,Use with caution in patients with renal impairment due to risk of hypercalcemia,May cause hypercalcemia; monitor calcium levels,Avoid in patients with digitalis toxicity due to risk of fatal arrhythmias
Narrow therapeutic index; serum theophylline levels must be monitored to avoid toxicity. Risk of seizures, cardiac arrhythmias, and death, especially at high serum concentrations. Caution in patients with hepatic impairment, congestive heart failure, cor pulmonale, fever, and in the elderly. Drug interactions with cimetidine, fluoroquinolones, macrolides, oral contraceptives, and other CYP1A2 inhibitors can increase toxicity.
Hypercalcemia,Severe hypercalciuria,Patients receiving digitalis (toxicity risk),Known hypersensitivity to calcium gluconate or any component of the formulation
Absolute: Hypersensitivity to theophylline, ethylenediamine, or any component; use in patients with active seizure disorder (unless receiving appropriate anticonvulsant therapy); use in patients with a history of ventricular arrhythmias (except under close supervision). Relative: Peptic ulcer disease, hyperthyroidism, hypertension, and renal impairment.
No significant food interactions, but avoid excessive dietary calcium intake (e.g., dairy, fortified foods) during therapy to prevent hypercalcemia. Caffeine and alcohol may affect calcium levels; limit intake.
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they can potentiate theophylline effects and increase risk of toxicity. A high-protein diet may increase theophylline clearance; maintain consistent dietary habits.
Calcium gluconate is a physiologic ion. No teratogenic effects are reported at therapeutic doses. Maternal calcium requirements increase during pregnancy, but exogenous calcium administration at standard doses is not associated with fetal malformations. However, maternal hypercalcemia (e.g., from excessive dosing) can lead to fetal hypoparathyroidism, hypotonia, and polyhydramnios, particularly in the third trimester.
Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only if benefit outweighs risk; may cause fetal tachycardia or irritability due to adenosine receptor blockade. Avoid near term due to potential neonatal irritability.
Calcium is a normal constituent of breast milk. Exogenous calcium gluconate administration increases maternal serum calcium transiently, but the effect on milk calcium concentration is minimal. The milk-to-plasma (M/P) ratio for calcium is approximately 0.1–0.3, indicating limited transfer. Use in breastfeeding mothers is considered compatible with breastfeeding when doses are within standard therapeutic ranges.
Not recommended unless essential. Aminophylline is excreted into breast milk; M/P ratio approximately 0.6–0.8. Monitor infant for irritability or insomnia. Consider alternative therapies if breastfeeding.
No dose adjustment required for standard calcium replacement or acute hypocalcemia treatment during pregnancy. However, due to increased calcium demand and altered renal handling (increased glomerular filtration rate), monitoring of serum calcium is recommended to avoid both hypo- and hypercalcemia. For IV administration in preeclampsia/eclampsia (as adjunct to magnesium sulfate), use standard non-pregnant dosing.
Pregnancy may decrease protein binding and increase clearance of theophylline; monitor serum levels closely. Dose may need to be increased by 10–30% to maintain therapeutic levels. Postpartum, doses may need reduction.
Calcium gluconate in sodium chloride (0.9% Na Cl) is used for intravenous calcium replacement. It provides 0.465 m Eq of calcium per m L (9.3 mg elemental calcium per m L). Infiltration causes severe tissue necrosis; use a central line if peripheral access is poor. Do not mix with bicarbonate, phosphate, or sulfate containing solutions (precipitates). Monitor ECG during infusion for bradycardia or arrhythmias. In cardiac arrest due to hyperkalemia or calcium channel blocker overdose, give 1 g IV push over 2-5 minutes with ECG monitoring. Extravasation: treat with hyaluronidase injection and warm compresses.
Aminophylline is a bronchodilator used primarily for asthma and COPD exacerbations. Monitor serum theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Administer IV infusion over 30 minutes to avoid hypotension. Caution in patients with cardiac arrhythmias, hyperthyroidism, or seizure disorders. Drug interactions include cimetidine, fluoroquinolones, and macrolides which increase theophylline levels.
Report any pain, redness, or swelling at the IV site immediately.,Inform your doctor if you have kidney stones, kidney disease, or sarcoidosis.,Avoid taking calcium supplements or vitamin D without doctor approval.,Do not consume large amounts of dairy products, antacids, or calcium-fortified foods unless directed.,This medication may cause a warm sensation, metallic taste, or flushing during infusion; tell your nurse if these occur.
Take this medication exactly as prescribed; do not stop or change dose without consulting your doctor.,Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects like jitteriness and palpitations.,Report any symptoms of toxicity such as nausea, vomiting, insomnia, rapid heart rate, or seizures immediately.,Inform your healthcare provider of all other medications, especially antibiotics, heart medications, or seizure drugs.,Do not chew or crush the solution; it is for intravenous use only under medical supervision.
"Calcium gluconate provides exogenous calcium, which can counteract the calcium channel blocking effect of nimodipine. This reduces nimodipine's ability to inhibit calcium influx into vascular smooth muscle cells, potentially decreasing its antihypertensive and vasodilatory efficacy. Clinically, coadministration may lead to reduced nimodipine effectiveness in preventing cerebral vasospasm after subarachnoid hemorrhage."
"Sodium glycerophosphate, an organic phosphate source, can chelate calcium ions in the gastrointestinal tract, forming insoluble calcium phosphate complexes. This reduces the absorption of orally administered calcium gluconate, leading to lower serum calcium concentrations. Clinically, this may result in diminished efficacy of calcium supplementation, potentially exacerbating hypocalcemia in susceptible patients."
"Calcium gluconate chelates deferiprone in the gastrointestinal tract, forming a non-absorbable complex that reduces deferiprone's bioavailability. This results in decreased serum concentrations and diminished therapeutic efficacy of deferiprone, potentially leading to inadequate chelation of iron in patients with iron overload. Clinically, patients may experience suboptimal reduction of serum ferritin and increased risk of iron-related organ damage."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CALCIUM GLUCONATE IN SODIUM CHLORIDE vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, answered by our medical review team.
CALCIUM GLUCONATE IN SODIUM CHLORIDE is a Electrolyte that works by Calcium gluconate provides calcium ions, which are essential for normal cardiac function, nerve transmission, and muscle contraction. In hyperkalemia, calcium antagonizes the cardiotoxic effects of potassium by stabilizing the cardiac cell membrane.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CALCIUM GLUCONATE IN SODIUM CHLORIDE and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CALCIUM GLUCONATE IN SODIUM CHLORIDE is: 1-2 g calcium gluconate (9.3-18.6 m Eq calcium) intravenously over 10-20 minutes, may repeat if needed. For continuous infusion: 0.5-2 mg/kg/hour calcium gluconate. Max rate: 1-2 m L/minute of 10% solution.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CALCIUM GLUCONATE IN SODIUM CHLORIDE and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CALCIUM GLUCONATE IN SODIUM CHLORIDE is classified as Category A/B. Calcium gluconate is a physiologic ion. No teratogenic effects are reported at therapeutic doses. Maternal calcium requirements increase during pregnancy, but exogenous calcium adm. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.